Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    VYNE Therapeutics Inc.

    NASDAQ: VYNE · Real-Time Price · USD
    0.90
    0.01 (1.15%)
    At close: Jun 13, 2025, 3:58 PM
    0.88
    -2.16%
    After-hours: Jun 13, 2025, 05:50 PM EDT

    VYNE Therapeutics Statistics

    Share Statistics

    VYNE Therapeutics has 16.66M shares outstanding. The number of shares has increased by 4.69% in one year.

    Shares Outstanding

    n/a
    		 16.66M

    Shares Change (YoY)

    n/a
    		 4.69%

    Shares Change (QoQ)

    n/a
    		 3.11%

    Owned by Institutions (%)

    n/a
    		 16.59%

    Shares Floating

    n/a
    		 13.61M

    Failed to Deliver (FTD) Shares

    n/a
    		 100

    FTD / Avg. Volume

    n/a
    		 0.04%

    Short Selling Information

    The latest short interest is 334.57K, so 2.01% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 334.57K

    Short % of Shares Out

    n/a
    		 2.01%

    Short % of Float

    n/a
    		 2.03%

    Short Ratio (days to cover)

    n/a
    		 1

    Valuation Ratios

    The PE ratio is -3.58 and the forward PE ratio is -1.22. VYNE Therapeutics's PEG ratio is 0.05.

    PE Ratio

    n/a
    		 -3.58

    Forward PE

    n/a
    		 -1.22

    PS Ratio

    n/a
    		 284.78

    Forward PS

    n/a
    		 1.1

    PB Ratio

    n/a
    		 2.74

    P/FCF Ratio

    n/a
    		 -4.19

    PEG Ratio

    n/a
    		 0.05
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for VYNE Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 4.35, with a Debt / Equity ratio of 0.

    Current Ratio

    n/a
    		 4.35

    Quick Ratio

    n/a
    		 4.35

    Debt / Equity

    n/a
    		 0

    Debt / EBITDA

    n/a
    		 n/a

    Debt / FCF

    n/a
    		 n/a

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $38,538.46

    Profits Per Employee

    n/a
    		 $-3,064,153.85

    Employee Count

    n/a
    		 13

    Asset Turnover

    n/a
    		 0.01

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 4K

    Effective Tax Rate

    n/a
    		 -0.01%

    Stock Price Statistics

    The stock price has increased by -60.87% in the last 52 weeks. The beta is 1.58, so VYNE Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 1.58

    52-Week Price Change

    n/a
    		 -60.87%

    50-Day Moving Average

    n/a
    		 1.31

    200-Day Moving Average

    n/a
    		 2.14

    Relative Strength Index (RSI)

    n/a
    		 28.33

    Average Volume (20 Days)

    n/a
    		 258,142

    Income Statement

    In the last 12 months, VYNE Therapeutics had revenue of 501K and earned -39.83M in profits. Earnings per share was -0.93.

    Revenue

    n/a
    		 501K

    Gross Profit

    n/a
    		 501K

    Operating Income

    n/a
    		 -43.64M

    Net Income

    n/a
    		 -39.83M

    EBITDA

    n/a
    		 -43.63M

    EBIT

    n/a
    		 -43.64M

    Earnings Per Share (EPS)

    n/a
    		 -0.93
    Full Income Statement

    Balance Sheet

    The company has 19.93M in cash and 99K in debt, giving a net cash position of 19.83M.

    Cash & Cash Equivalents

    n/a
    		 19.93M

    Total Debt

    n/a
    		 99K

    Net Cash

    n/a
    		 19.83M

    Retained Earnings

    n/a
    		 -731.17M

    Total Assets

    n/a
    		 56.42M

    Working Capital

    n/a
    		 42.62M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -33.97M and capital expenditures -117K, giving a free cash flow of -34.09M.

    Operating Cash Flow

    n/a
    		 -33.97M

    Capital Expenditures

    n/a
    		 -117K

    Free Cash Flow

    n/a
    		 -34.09M

    FCF Per Share

    n/a
    		 -0.8
    Full Cash Flow Statement

    Margins

    Gross margin is 99.2%, with operating and profit margins of -8709.98% and -7950.9%.

    Gross Margin

    n/a
    		 99.2%

    Operating Margin

    n/a
    		 -8709.98%

    Pretax Margin

    n/a
    		 -7944.71%

    Profit Margin

    n/a
    		 -7950.9%

    EBITDA Margin

    n/a
    		 -8709.18%

    EBIT Margin

    n/a
    		 -8709.98%

    FCF Margin

    n/a
    		 -6804.19%

    Dividends & Yields

    VYNE does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for VYNE is $6.25, which is 594.4% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $6.25

    Price Target Difference

    n/a
    		 594.4%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 2
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Stock Splits

    The last stock split was on Feb 13, 2023. It was a backward split with a ratio of 1:18.

    Last Split Date

    n/a
    		 Feb 13, 2023

    Split Type

    n/a
    		 backward

    Split Ratio

    n/a
    		 1:18

    Scores

    Altman Z-Score

    n/a
    		 -19.28

    Piotroski F-Score

    n/a
    		 1

    Add to Watchlist